CD34 and myelodysplastic syndrome: Similarly, Medyouf et al. demonstrated that the co-injection of patient-derived MDS CD34+ cells with MSCs led to efficient engraftments (70%) in NSG mice with the resulting xenograft model displaying dysplasia and characteristic molecular lesions [36].